MESOM
MCID: MST023
MIFTS: 59

Mesothelioma, Malignant (MESOM)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Mesothelioma, Malignant

MalaCards integrated aliases for Mesothelioma, Malignant:

Name: Mesothelioma, Malignant 57 53 74 29 6 44 40
Malignant Mesothelioma 12 53 55 15 17 72
Pleural Mesothelioma 59 17 72
Advanced Malignant Mesothelioma 12 72
Mesothelioma 72 33
Mesom 57 74
Malignant Mesothelioma, Susceptibility to 13
Asbestos-Related Malignant Mesothelioma 12
Diffuse Malignant Mesothelioma 12
Malignant Tumor of Mesothelium 12
Malignant Pleural Mesothelioma 72
Mesothelioma Diffuse Malignant 55
Mesothelioma, Somatic 57

Characteristics:

Orphanet epidemiological data:

59
pleural mesothelioma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

OMIM:

57
Inheritance:
somatic mutation

Miscellaneous:
etiologically linked to asbestos
may be seen in conjunction with other cancer syndromes (e.g., tdps )


HPO:

32
mesothelioma, malignant:
Inheritance somatic mutation


Classifications:

Orphanet: 59  
Rare respiratory diseases


External Ids:

Disease Ontology 12 DOID:1790
OMIM 57 156240
SNOMED-CT 68 62064005
ICD10 33 C45 C45.9
MESH via Orphanet 45 D008654
ICD10 via Orphanet 34 C45.0
UMLS via Orphanet 73 C0025500 C0812413 C1377913
Orphanet 59 ORPHA50251
MedGen 42 C0345967
UMLS 72 C0278752 C0345967 C0392400 more

Summaries for Mesothelioma, Malignant

NIH Rare Diseases : 53 Malignant mesothelioma is a form of cancer that develops in the thin layer of tissue that surrounds the lungs, chest wall, or abdomen. Signs and symptoms of the condition can vary and often depend on which area of the body is affected. Common features include abdominal bloating, abdominal pain, chest pain, coughing, fatigue, shortness of breath, and/or weight loss. Malignant mesothelioma is thought to be caused by long-term exposure to asbestos (a fire-resistant material that was once commonly found in insulation; ceiling and roof vinyls; cement; and automotive brake materials). Most people appear to be diagnosed with the condition approximately 30 years after being in contact with the asbestos. Unfortunately, there is generally no cure for malignant mesothelioma unless it is diagnosed at an early stage and can be surgically removed. If surgery is not an option, chemotherapy and/or radiation therapy may still be recommended to help alleviate some of the associated symptoms.

MalaCards based summary : Mesothelioma, Malignant, also known as malignant mesothelioma, is related to malignant epithelial mesothelioma and malignant peritoneal mesothelioma, and has symptoms including fatigue, dyspnea and chest pain. An important gene associated with Mesothelioma, Malignant is BCL10 (BCL10 Immune Signaling Adaptor), and among its related pathways/superpathways are MicroRNAs in cancer and Adhesion. The drugs Deoxyglucose and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include lung, testis and t cells, and related phenotypes are pleural effusion and weight loss

Disease Ontology : 12 A cell type cancer that has material basis in mesothelial tissue that develops from the thin layer of tissue that covers many of the internal organs.

OMIM : 57 Malignant mesothelioma is an aggressive neoplasm of the serosal lining of the chest etiologically linked to asbestos. It is diagnosed in approximately 2,000 to 3,000 individuals annually in the United States, most of whom die within 2 years of diagnosis (summary by Bott et al., 2011). See also 614327 for a tumor predisposition syndrome that may contribute to the development of malignant mesothelioma upon asbestos exposure and is caused by germline mutation in the BAP1 gene (603089) on chromosome 3p21. (156240)

UniProtKB/Swiss-Prot : 74 Mesothelioma, malignant: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos.

Wikipedia : 75 Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the... more...

Related Diseases for Mesothelioma, Malignant

Diseases in the Benign Mesothelioma family:

Mesothelioma, Malignant Benign Intermediate Mesothelioma

Diseases related to Mesothelioma, Malignant via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 738)
# Related Disease Score Top Affiliating Genes
1 malignant epithelial mesothelioma 33.4 WT1 THBD
2 malignant peritoneal mesothelioma 33.2 NF2 MUC1 CDKN2A
3 peritoneal mesothelioma 32.7 WT1 THBD NF2 MUC1 CDKN2A
4 benign mesothelioma 32.6 WT1 KRT7
5 malignant pleural mesothelioma 32.3 WT1 THBD NKX2-1 MUC1 MSLN CDKN2A
6 pericardial mesothelioma 32.2 THBD MUC1 MSLN KRT7 CALB2
7 sarcomatoid mesothelioma 32.0 WT1 THBD NKX2-1 MUC1 CDKN2A
8 malignant biphasic mesothelioma 32.0 WT1 THBD MSLN KRT7 CALB2
9 sarcoma, synovial 30.8 MUC1 KRT7 CALB2
10 small cell carcinoma 30.7 NKX2-1 KRT7 CDKN2A
11 spindle cell sarcoma 30.7 NF2 MUC1 KRT7
12 secretory meningioma 30.7 MUC1 KRT7
13 lymphohistiocytoid mesothelioma 30.6 THBD CDKN2A CALB2
14 malignant peripheral nerve sheath tumor 30.6 NF2 MUC1 CDKN2A
15 monophasic synovial sarcoma 30.5 MUC1 KRT7
16 endosalpingiosis 30.5 WT1 MUC1 KRT7
17 fibrous meningioma 30.5 NF2 MUC1
18 diffuse peritoneal leiomyomatosis 30.5 WT1 CALB2
19 papillary carcinoma 30.5 NKX2-1 MUC1 KRT7
20 pleural cancer 30.4 WT1 NF2 MSLN CDKN2A CALB2
21 papillary adenocarcinoma 30.4 NKX2-1 MUC1 KRT7
22 renal cell carcinoma, nonpapillary 30.3 WT1 NKX2-1 MUC1 MIR584 KRT7
23 adenomyoma 30.2 MUC1 KRT7
24 intestinal perforation 30.2 NKX2-1 KRT7
25 polycystic liver disease 1 with or without kidney cysts 30.1 MUC1 KRT7 CALB2
26 adenomatoid tumor 30.1 WT1 THBD KRT7 CALB2
27 small cell cancer of the lung 30.1 NKX2-1 KRT7 CDKN2A
28 cystadenofibroma 29.9 MUC1 KRT7 CALB2
29 well-differentiated liposarcoma 29.9 MUC1 KRT7 CDKN2A
30 pericardium cancer 29.9 THBD MSLN KRT7 CALB2
31 ovarian brenner tumor 29.9 WT1 THBD KRT7 CALB2
32 chordoma 29.8 MUC1 KRT7 CDKN2A
33 mucinous adenocarcinoma 29.8 NKX2-1 MUC1 KRT7 CDKN2A
34 lung cancer susceptibility 3 29.5 NKX2-1 MUC1 MSLN KRT7 CDKN2A CDH2
35 benign multicystic peritoneal mesothelioma 12.5
36 peritoneal cystic mesothelioma 12.5
37 ovarian malignant mesothelioma 12.3
38 bap1 tumor predisposition syndrome 12.0
39 tumor predisposition syndrome 11.8
40 uterine corpus adenomatoid tumor 11.1
41 epididymis adenomatoid tumor 11.1
42 fallopian tube carcinosarcoma 10.8 WT1 CALB2
43 fallopian tube squamous cell carcinoma 10.8 WT1 CDKN2A
44 optic nerve sheath meningioma 10.7 NF2 CDKN2A
45 transitional meningioma 10.7 NF2 MUC1
46 melanomatosis 10.7 WT1 CDKN2A
47 cornea cancer 10.7 NF2 CDKN2A
48 renal adenoma 10.7 WT1 KRT7
49 peritoneal benign neoplasm 10.7 WT1 CALB2
50 epithelial predominant wilms' tumor 10.7 WT1 KRT7

Graphical network of the top 20 diseases related to Mesothelioma, Malignant:



Diseases related to Mesothelioma, Malignant

Symptoms & Phenotypes for Mesothelioma, Malignant

Human phenotypes related to Mesothelioma, Malignant:

59 32 (show all 19)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pleural effusion 59 32 hallmark (90%) Very frequent (99-80%) HP:0002202
2 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
3 respiratory distress 59 32 frequent (33%) Frequent (79-30%) HP:0002098
4 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
5 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
6 dysphagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002015
7 hepatomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0002240
8 lymphadenopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0002716
9 fourth cranial nerve palsy 59 32 occasional (7.5%) Occasional (29-5%) HP:0007011
10 obstruction of the superior vena cava 59 32 occasional (7.5%) Occasional (29-5%) HP:0031041
11 abnormal cardiovascular system physiology 32 occasional (7.5%) HP:0011025
12 dyspnea 59 Frequent (79-30%)
13 abnormality of the thorax 59 Frequent (79-30%)
14 abnormality of the pleura 59 Frequent (79-30%)
15 functional respiratory abnormality 59 Occasional (29-5%)
16 abnormal lung morphology 59 Occasional (29-5%)
17 abnormality of cardiovascular system physiology 59 Occasional (29-5%)
18 constitutional symptom 59 Frequent (79-30%)
19 malignant mesothelioma 32 HP:0100001

Symptoms via clinical synopsis from OMIM:

57
Respiratory Lung:
mesothelioma, malignant

Neoplasia:
mesothelioma

Clinical features from OMIM:

156240

UMLS symptoms related to Mesothelioma, Malignant:


fatigue, dyspnea, chest pain, chills, malaise

Drugs & Therapeutics for Mesothelioma, Malignant

Drugs for Mesothelioma, Malignant (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 312)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Deoxyglucose Phase 4
2
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
3
Methylcobalamin Approved, Experimental, Investigational Phase 2, Phase 3 13422-55-4
4
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840
5
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
nivolumab Approved Phase 2, Phase 3 946414-94-4
9
Ipilimumab Approved Phase 2, Phase 3 477202-00-9
10
Nintedanib Approved Phase 2, Phase 3 656247-17-5 56843413
11
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
12 Ranpirnase Investigational Phase 3 196488-72-9
13
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
14 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
15 Micronutrients Phase 3
16 Trace Elements Phase 3
17 Vitamins Phase 2, Phase 3
18 Vitamin B 12 Phase 2, Phase 3
19 Nutrients Phase 3
20 Vitamin B12 Phase 2, Phase 3
21 BB 1101 Phase 3
22 Autonomic Agents Phase 3
23 Narcotics Phase 3
24 Analgesics, Opioid Phase 3
25 Interferon-alpha Phase 3
26 Interferon alpha-2 Phase 3
27 Vinca Alkaloids Phase 3
28
Vinblastine Approved Phase 2 865-21-4 241903 13342
29
Megestrol acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 595-33-5 11683
30
Heparin Approved, Investigational Phase 2 9005-49-6 46507594 772
31
Ibuprofen Approved Phase 2 15687-27-1 3672
32
Selenious acid Approved, Investigational Phase 1, Phase 2 7783-00-8
33
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
34
Belinostat Approved, Investigational Phase 2 866323-14-0
35
Epirubicin Approved Phase 2 56420-45-2 41867
36
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
37
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
38
Axitinib Approved, Investigational Phase 1, Phase 2 319460-85-0 6450551
39
tannic acid Approved Phase 2 1401-55-4
40
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
41
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
42
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 40926 439693
43
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
44
Zoledronic Acid Approved Phase 2 118072-93-8 68740
45
Tamoxifen Approved Phase 2 10540-29-1 2733526
46
Sodium citrate Approved, Investigational Phase 2 68-04-2
47
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
48
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
49
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
50
Promethazine Approved, Investigational Phase 2 60-87-7 4927

Interventional clinical trials:

(show top 50) (show all 445)
# Name Status NCT ID Phase Drugs
1 Pharmacokinetics of Carboplatin After Adjusted Dosing for High BMI, Low Serum Creatinine, and Maximal Renal Function Unknown status NCT02103244 Phase 4 Carboplatin
2 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
3 Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
4 Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response Recruiting NCT03655834 Phase 4 Pemetrexed
5 Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response Recruiting NCT03655821 Phase 4 Pemetrexed
6 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
7 ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
8 Phase III Study of Tomudex and Cisplatin Versus Cisplatin in Malignant Pleural Mesothelioma Completed NCT00004920 Phase 3 cisplatin;raltitrexed
9 A Randomized Controlled Trial of Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3 cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
10 A Single-Blind Randomized Phase III Trial of MTA Plus Cisplatin Versus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00005636 Phase 3 cisplatin;pemetrexed disodium
11 A Randomized Phase 3 Trial Comparing ALIMTA Plus Best Supportive Care Versus Best Supportive Care Alone in Previously Treated Patients With Locally Advanced or Metastatic Malignant Pleural Mesothelioma Completed NCT00190762 Phase 3 Pemetrexed
12 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy Completed NCT00128102 Phase 3 vorinostat;Placebo
13 A Randomized Study to Assess Whether Radiotherapy Prevents Skin Lumps at Sites Where Needles or Tubes Have Been Inserted in Patients With Malignant Mesothelioma Completed NCT00006231 Phase 3
14 NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM) Completed NCT01098266 Phase 3 NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
15 A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM) Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
16 Prospective Randomised Controlled Trial of Video-Assisted Thoracoscopic (VAT) Cytoreductive Pleurectomy Compared to Talc Pleurodesis in Patients With Suspected or Proven Malignant Mesothelioma Completed NCT00821860 Phase 3
17 Phase III Trial of Single-Agent Pemetrexed (Alimta®) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2 Completed NCT01836575 Phase 3 Pemetrexed;Carboplatin
18 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
19 Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesothelioma With Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study) Recruiting NCT02709512 Phase 2, Phase 3 ADI-PEG 20 plus Pem Cis
20 A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma Recruiting NCT03762018 Phase 3 Carboplatin;Pemetrexed;Bevacizumab;Atezolizumab
21 A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Recruiting NCT02784171 Phase 2, Phase 3 Cisplatin;Pemetrexed;Pembrolizumab
22 A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma Recruiting NCT03710876 Phase 3 Celecoxib Oral Product;Gemcitabine
23 CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma Recruiting NCT03063450 Phase 3 Nivolumab
24 A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy Recruiting NCT03610360 Phase 2, Phase 3 MesoPher
25 A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma Active, not recruiting NCT02991482 Phase 3 Pembrolizumab;Gemcitabine;Vinorelbine
26 A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Active, not recruiting NCT02899299 Phase 3 Pemetrexed;Cisplatin;Carboplatin
27 Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies Active, not recruiting NCT02349412 Phase 3
28 Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma Not yet recruiting NCT03918252 Phase 2, Phase 3 Nivolumab Injection;Ipilimumab Injection
29 LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma Terminated NCT01907100 Phase 2, Phase 3 Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
30 PIT: A Phase III Randomised Trial of Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Following Invasive Chest Wall Intervention Terminated NCT01604005 Phase 3
31 A Randomized Phase III Trial to Compare the Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication for Mesothelioma or Other Pathologies Withdrawn NCT02511600 Phase 3
32 A Randomized Stratified Multicentre Phase II Clinical Trial of Single Agent ADI-PEG 20TM (Pegylated Arginine Deiminase) in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2 ADI-PEG 20
33 Aggressive Multi-Modality Management of Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
34 Four Versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelioma; a Randomized Phase II Study Unknown status NCT02497053 Phase 2 pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
35 A Pilot And Feasibility Trial Evaluating Two Different Chemotherapy Regimens In Combination With Intrapleural Adenoviral-Mediated Interferon-Alpha Gene Transfer For Malignant Pleural Mesothelioma Unknown status NCT01119664 Phase 1, Phase 2 SCH 721015
36 Phase II Study of Six Hours, Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma. Unknown status NCT01869023 Phase 2 Gemcitabine;Cisplatin
37 "Phase II Study: Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma " Unknown status NCT00886028 Phase 2 Liposomal doxorubicin;Cisplatin
38 A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma Unknown status NCT02303899 Phase 2 Gemcitabine;Imatinib mesylate
39 Phase II, A Study of Lung-Sparing Combined Modality Protocol for the Treatment for Malignant Pleural Mesothelioma: The Columbia Protocol Unknown status NCT00859495 Phase 2 Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
40 A Phase II Trial to Assess the Safety, Immunological Activity of TroVax® Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2 Pemetrexed;Cisplatin;Dexamethasone
41 A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit Unknown status NCT00551252 Phase 2 Imatinib mesylate plus Gemcitabine
42 Randomized Feasibility Study Of Active Symptom Control With Or Without Chemotherapy In The Treatment Of Patients With Mesothelioma Unknown status NCT00030459 Phase 2 cisplatin;mitomycin C;vinblastine sulfate;vinorelbine tartrate
43 A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1 Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
44 Oxaliplatin (Eloxatin®) Plus Gemcitabine as First or Second-line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial Unknown status NCT00859469 Phase 2 Oxaliplatin/Gemcitabine
45 Phase I/II Study of High-Dose Megestrol in Breast or Endometrial Carcinoma or Mesothelioma Unknown status NCT00002465 Phase 1, Phase 2 megestrol acetate
46 Phase I-Ib Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Advanced or Metastatic Cancer Suitable for a Carboplatin and Pemetrexed Regimen as Part of Their Specific Therapy Unknown status NCT02049060 Phase 1, Phase 2 Tivantinib
47 Trial of Sorafenib in Malignant Mesothelioma Previously Treated With Platinum-based Chemotherapy Unknown status NCT00794859 Phase 2 Sorafenib
48 A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
49 A Second-line, Single Arm, Phase II Clinical Study With Tremelimumab, a Fully Human Anti-CTLA-4 Monoclonal Antibody as Monotherapy in Patients With Unresectable Malignant Mesothelioma Unknown status NCT01649024 Phase 2 Tremelimumab
50 A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMAN ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA. The MESOT-TREM-2012 Unknown status NCT01655888 Phase 2 Tremelimumab

Search NIH Clinical Center for Mesothelioma, Malignant

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cisplatin
Mitomycin
Pemetrexed
Raltitrexed

Cochrane evidence based reviews: mesothelioma, malignant

Genetic Tests for Mesothelioma, Malignant

Genetic tests related to Mesothelioma, Malignant:

# Genetic test Affiliating Genes
1 Mesothelioma, Malignant 29 BCL10 WT1

Anatomical Context for Mesothelioma, Malignant

MalaCards organs/tissues related to Mesothelioma, Malignant:

41
Lung, Testis, T Cells, Breast, Heart, Lymph Node, Testes

Publications for Mesothelioma, Malignant

Articles related to Mesothelioma, Malignant:

(show top 50) (show all 4667)
# Title Authors PMID Year
1
Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. 9 38 8
7494231 1995
2
A cluster of familial malignant mesothelioma with del(9p) as the sole chromosomal anomaly. 38 8
12419589 2002
3
Neurofibromatosis 2 and malignant mesothelioma. 38 8
12136076 2002
4
Familial malignant mesothelioma. 38 8
11734267 2001
5
Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. 38 8
11273069 2001
6
Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. 38 8
9927061 1999
7
Familial pleural malignant mesothelioma: clustering in three sisters and one cousin. 38 8
9751275 1998
8
Familial mesothelioma: review and family study. 38 8
3967217 1985
9
Malignant mesothelioma in two pairs of siblings: is there a hereditary predisposing factor? 38 8
6723827 1984
10
Familial clustering of malignant mesothelioma. 38 8
7379039 1980
11
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. 8
21642991 2011
12
CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis. 38 88
19396864 2009
13
Lack of Bcl10 mutations in testicular germ cell tumours and derived cell lines. 71
10408400 1999
14
Lack of BCL10 mutations in germ cell tumors and B cell lymphomas. 71
10380920 1999
15
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 71
9989495 1999
16
Asbestos and mesothelioma: genetic lessons from a tragedy. 8
7479890 1995
17
Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour. 71
8298644 1993
18
Asbestos-contaminated nappies and familial mesothelioma. 8
2564999 1989
19
Familial mesothelioma: a report of two families. 8
2914699 1989
20
Familial mesothelioma after intense asbestos exposure at home. 8
660896 1978
21
An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/Urgüp in Anatolia. 8
663877 1978
22
Household-contact asbestos neoplastic risk. 8
1069520 1976
23
Ultrastructure and observations on the histogenesis of mesotheliomas, "adenomatoid tumors", of the female genital tract. 71
4332312 1972
24
Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model. 9 38
20072072 2010
25
9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. 9 38
20518890 2010
26
Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. 9 38
20146302 2010
27
Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. 9 38
19523712 2010
28
Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. 9 38
20131968 2010
29
Well-differentiated papillary mesothelioma with invasion to the chest wall. 9 38
19880210 2010
30
Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. 9 38
19740516 2010
31
[Malignant peritoneal mesothelioma]. 9 38
20445731 2010
32
Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. 9 38
19843662 2009
33
Malignant mesothelioma of the greater omentum mimicking omental infarction: a case report. 9 38
19824125 2009
34
Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. 9 38
19451229 2009
35
Serum and pleural fluid biomarkers for mesothelioma. 9 38
19417672 2009
36
An EMA negative, desmin positive malignant mesothelioma: limitations of immunohistochemistry? 9 38
19561235 2009
37
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. 9 38
19380521 2009
38
Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. 9 38
19285954 2009
39
Pooled analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma. 9 38
18838334 2009
40
Placenta growth factor is a survival factor for human malignant mesothelioma cells. 9 38
19505392 2009
41
[A case of IL-6 producing malignant mesothelioma of abdomen with thrombocytosis]. 9 38
19346724 2009
42
Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. 9 38
19289587 2009
43
Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers. 9 38
19261093 2009
44
Clinical utility of diagnostic markers for malignant pleural mesothelioma. 9 38
19522163 2009
45
Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies. 9 38
19152187 2009
46
Osteopontin levels in an asbestos-exposed population. 9 38
19174489 2009
47
The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells. 9 38
19176370 2009
48
A binding domain on mesothelin for CA125/MUC16. 9 38
19075018 2009
49
Interaction of onconase with the human ribonuclease inhibitor protein. 9 38
18930025 2008
50
mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. 9 38
18511708 2008

Variations for Mesothelioma, Malignant

ClinVar genetic disease variations for Mesothelioma, Malignant:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 WT1 NM_024426.6(WT1): c.1303C> T (p.Arg435Ter) single nucleotide variant Pathogenic rs121907906 11:32414263-32414263 11:32392717-32392717
2 WT1 NM_024426.6(WT1): c.1036A> G (p.Ser346Gly) single nucleotide variant Pathogenic rs121907908 11:32421571-32421571 11:32400025-32400025
3 BCL10 NM_003921.5(BCL10): c.499dup (p.Ser167fs) duplication Pathogenic rs387906350 1:85733513-85733513 1:85267830-85267830
4 BCL10 NM_003921.5(BCL10): c.136del (p.Ile46fs) deletion Pathogenic rs387906351 1:85736511-85736511 1:85270828-85270828
5 WT1 NM_024426.6(WT1): c.314C> G (p.Ala105Gly) single nucleotide variant Uncertain significance rs948061247 11:32456593-32456593 11:32435047-32435047

Copy number variations for Mesothelioma, Malignant from CNVD:

7 (show all 35)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13405 1 1 2300000 Loss Malignant mesothelioma
2 21838 1 16200000 28000000 Loss Malignant mesothelioma
3 33950 1 50700000 61300000 Amplification Malignant mesothelioma
4 35952 1 69700000 116100000 Loss Malignant mesothelioma
5 35954 1 69700000 116100000 Loss CLCA1 Malignant mesothelioma
6 35956 1 69700000 116100000 Loss CLCA2 Malignant mesothelioma
7 35958 1 69700000 116100000 Loss CLCA3 Malignant mesothelioma
8 35960 1 69700000 116100000 Loss CLCA4 Malignant mesothelioma
9 35962 1 69700000 116100000 Loss COL11A1 Malignant mesothelioma
10 35964 1 69700000 116100000 Loss TGFBR3 Malignant mesothelioma
11 35966 1 69700000 120600000 Loss Malignant mesothelioma
12 37056 1 84900000 107200000 Loss Malignant mesothelioma
13 69952 12 56600000 58100000 Gain Malignant mesothelioma
14 75172 13 17900000 45800000 Loss BRCA2 Malignant mesothelioma
15 85738 14 50900000 107349540 Loss CCNK Malignant mesothelioma
16 85740 14 50900000 107349540 Loss CDKN3 Malignant mesothelioma
17 113645 17 44900000 81195210 Gain ERN1 Malignant mesothelioma
18 113647 17 44900000 81195210 Gain MAP3K3 Malignant mesothelioma
19 113649 17 44900000 81195210 Gain PRKCA Malignant mesothelioma
20 113651 17 44900000 81195210 Gain SMARCD2 Malignant mesothelioma
21 175422 3 39400000 63700000 Loss CACNA2D3 Malignant mesothelioma
22 175424 3 39400000 63700000 Loss CTNNB1 Malignant mesothelioma
23 175426 3 39400000 63700000 Loss MLH1 Malignant mesothelioma
24 175771 3 44100000 44200000 Loss Malignant mesothelioma
25 187512 4 50400000 191154276 Loss Malignant mesothelioma
26 191705 5 1 48400000 Gain Malignant mesothelioma
27 204729 6 114600000 118300000 Loss HDAC2 Malignant mesothelioma
28 204731 6 114600000 118300000 Loss MARCKS Malignant mesothelioma
29 217075 7 1 4500000 Gain Malignant mesothelioma
30 234871 8 139900000 146364022 Gain Malignant mesothelioma
31 250026 9 19900000 25600000 Loss C9orf14 Malignant mesothelioma
32 250029 9 19900000 25600000 Loss CDKN2A Malignant mesothelioma
33 250031 9 19900000 25600000 Loss CDKN2B Malignant mesothelioma
34 250069 9 19900000 33200000 Loss Malignant mesothelioma
35 251883 9 33200000 36300000 Gain Malignant mesothelioma

Expression for Mesothelioma, Malignant

Search GEO for disease gene expression data for Mesothelioma, Malignant.

Pathways for Mesothelioma, Malignant

Pathways related to Mesothelioma, Malignant according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.51 MIR615 MIR483 MIR345 MIR203A CDKN2A
2 11.22 MUC1 MSLN CDH2

GO Terms for Mesothelioma, Malignant

Biological processes related to Mesothelioma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.17 MIR885 MIR615 MIR584 MIR582 MIR483 MIR345
2 negative regulation of cell-matrix adhesion GO:0001953 8.96 NF2 CDKN2A

Molecular functions related to Mesothelioma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR582 MIR483 MIR345 MIR203A

Sources for Mesothelioma, Malignant

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....